Drug intelligence / Profile preview

CTX-472

Development stage: Preclinical
Lead developer: Combined Therapeutics
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

CTX-472 is a preclinical-stage vaccine candidate being developed by Combined Therapeutics for the prevention of infectious diseases. Utilizing the company's proprietary Multi-Organ Protection (MOPCTx) platform, CTX-472 is designed as an adjuvanted mRNA vaccine. The platform incorporates tissue-selective mRNA translation by utilizing microRNA (miRNA) binding sequences in the untranslated regions (UTRs) of the mRNA, which restricts antigen and adjuvant expression to the site of injection (intramuscular) while protecting vital organs such as the heart, liver, and kidneys from off-target effects. This approach aims to induce a robust and durable immune response with an improved safety and tolerability profile.

Beyond the preview

Go deeper on CTX-472.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTX-472.

Explore the full profile